Literature DB >> 28130325

Concordance of Barthel Index, ECOG-PS, and Palliative Performance Scale in the assessment of functional status in patients with advanced medical diseases.

C Hernández-Quiles1, M Bernabeu-Wittel1, L M Pérez-Belmonte2, P Macías-Mir3, D Camacho-González3, B Massa4, M Maiz-Jiménez2, M Ollero-Baturone1.   

Abstract

OBJECTIVE: Analysing most relevant clinical features and concordance between different functional scales in patients with advanced medical diseases (PAMD).
METHODS: Cross-sectional multicentre study that included PAMD (heart, lung, kidney, liver, and neurological diseases) in hospital settings from February 2009 to October 2010. We analysed clinical, biological and functional features in performing activities of daily living (ADL) by medians of Barthel Index (BI); additionally we assessed their performance status by medians of Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) and Palliative Performance Scale (PPS) scores. We evaluated the concordance of these instruments in assessing functional impairment by κ and intraclass correlation coefficient tests.
RESULTS: 1847 patients were included (average age 79 years, 50.1% men). Most common symptoms were dyspnoea (62.31%), asthenia (23%) and delirium (20.14%). Functional assessment showed a high prevalence of severe or total impairment in performing basic ADL by medians of used instruments (BI median=35 (IQR=70), and 52.1% of patients with severe-total impairment; ECOG-PS median=2 (IQR 30), and 44% of patients with severe-total impairment; and PPS median=50 (IQR 30), and 32% of patients with severe-total impairment). Concordance among these instruments was acceptably good (κ indexes ranging from 0.653 to 0.745 (p<0.0001)).
CONCLUSIONS: PAMD represent a population with severe functional impairment, which requires a multidisciplinary approach for proper management. Assessment of functional ability in this population by BI, ECOG-PS, and PPS showed good concordance. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Chronic diseases; functional status; multimorbidity; performance status; polypathological patient; polypathology

Mesh:

Year:  2017        PMID: 28130325     DOI: 10.1136/bmjspcare-2015-001073

Source DB:  PubMed          Journal:  BMJ Support Palliat Care        ISSN: 2045-435X            Impact factor:   3.568


  4 in total

1.  [A German version of the Palliative Performance Scale (PPS) as a supportive structure to assess survival in palliative patients].

Authors:  Veronika Mosich; Martin Andersag; Herbert Watzke
Journal:  Wien Med Wochenschr       Date:  2019-11-14

2.  Meta‑analysis of current chemotherapy regimens in advanced pancreatic cancer to prolong survival and reduce treatment‑associated toxicities.

Authors:  Jie Chen; Linli Chen; Jianping Yu; Yanmei Xu; Xiaohui Wang; Ziqian Zeng; Ning Liu; Fan Xu; Shu Yang
Journal:  Mol Med Rep       Date:  2018-11-09       Impact factor: 2.952

3.  Impact of pre-OP independence in patients with limited brain metastases on long-term survival.

Authors:  Annalen Bleckmann; Benjamin Kirchner; Manuel Nietert; Micha Peeck; Marko Balkenhol; Daniela Egert; T Veit Rohde; Tim Beißbarth; Tobias Pukrop
Journal:  BMC Cancer       Date:  2020-10-08       Impact factor: 4.430

4.  Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.

Authors:  Hironaga Satake; Yoshinori Kagawa; Eiji Shinozaki; Yoshinori Tanizawa; Long Jin; Zhihong Cai; Akitaka Makiyama
Journal:  Adv Ther       Date:  2022-04-06       Impact factor: 4.070

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.